Allergic skin disease encompasses multiple conditions—atopic dermatitis, food-induced allergic dermatitis, and flea allergy dermatitis—that collectively affect a significant proportion of the dog population and cause substantial welfare compromise through chronic pruritus.
Flea allergy dermatitis (FAD) is the most common allergic skin condition in dogs. Even a single flea bite triggers intense pruritic responses in sensitised dogs—the entire body is affected despite localised flea bites. Signs concentrate on the lumbosacral area, tail base, and inguinal regions. Strict, year-round flea prevention using licensed prescription-strength products (isoxazolines, spot-ons) is the cornerstone of FAD management. Over-the-counter products are often ineffective. Environmental treatment reduces household flea burden.
Food allergy (more accurately, cutaneous adverse food reaction, CAFR) causes non-seasonal pruritus, recurrent ear infections, and gastrointestinal signs in some dogs. Diagnosis requires a strict dietary elimination trial using a novel protein or hydrolysed diet for minimum 8-12 weeks, with no dietary deviations (including treats, flavoured medications, or scavenged items). Many dogs with suspected CAFR are not genuinely food allergic when rigorously tested—accurate diagnosis avoids unnecessary lifelong dietary restriction.
Most allergic dogs are sensitive to multiple allergens simultaneously. The "threshold effect" means that when total allergen load exceeds the individual's threshold, signs appear; management below the threshold keeps signs controlled. This explains why apparently small changes—adding flea allergy to atopic dermatitis—cause disproportionate worsening. Multi-modal management addressing all identified allergens reduces total burden and maintains control where single-allergen management fails.
Allergen-specific immunotherapy (ASIT) addresses the underlying immune sensitisation rather than symptoms alone. Following intradermal testing or serum allergen-specific IgE testing identifying significant allergens, custom immunotherapy formulations are administered subcutaneously or sublingually on a graduated schedule. Response rates of 50-70% make ASIT the only disease-modifying treatment and the gold standard for appropriately selected atopic dogs with identified allergens.
Chronic allergic disease requires sustained owner commitment—monitoring for flares, maintaining flea prevention, dietary compliance, and medication administration. Owner burnout from managing chronic skin disease can lead to reduced compliance and deteriorating welfare. Veterinary support systems including nurse-led allergy clinics, clear written management plans, and realistic expectation setting regarding long-term management rather than cure improve compliance and welfare outcomes for chronically allergic dogs.